Evaluation of the use of PPIs and H2 receptor blockers in inpatient department of general medicine in a teaching hospital in Bengaluru
DOI:
https://doi.org/10.56511/JIPBS.2016.v3.i02.pp134-140Abstract
H2 –receptor antagonists like Ranitidine, which is the first-choice H2 –receptor antagonist in most patients. Proton pump inhibitors (PPIs) like Omeprazole, Lansoprazole and Pantoprazole. Produce profound gastric acid suppression and are the most effective treatment for gastro -esophageal reflux disease. They are also effective short-term treatments for gastric and duodenal ulcers. They may achieve a faster healing rate than H2-receptor antagonists, but the relapse rate is similar. Inappropriate use of antisecretory agents can produce further problems in patients so the appropriateness of antisecretory agents is the main objective of the present study, which should be accordance to standard treatment guidelines. This study is a hospital based prospective and observational study conducted at multispecialty teaching hospital over a period of 6 months. All the patients above the age of 18 years who were on antisecretory drugs prescription and willing to give consent were included in the study. Out of 139 patients enrolled in the study, it was observed that Pantoprazole in 29 (26.60%) followed by Rabeprazole 26 (23.85%), and Ranitidine in 11 (10.09%). Out of 138 patients prescribed with antisecretory medications the average cost of treatment was for rabeprazole (Rs.788.08) followed by pantoprazole (Rs.578.65), ranitidine (Rs.83.67) and omeprazole (Rs.312). Our study highlights the need of rational drug use practices like prescribing by generics and drugs under essential drug list. Continuing education about rational drug use and development of easy to use treatment guidelines for common diseases in General Medicine Department is recommended.
Keywords:
Quality of use, PPIs, Antisecretory Drugs, H2receptor blockersDownloads
References
Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ: Proton pump inhibitors: A survey of prescribing in an Irish general hospital. International Journal of Clinical Practice 2005; 59:31-34.
Maclaren R, Obritsch MD, Sherman DS, Jung R, Fish DN:Assessing adherence to an intravenous pantoprazole guideline. Journal of Pharmacology &Technology 2006; 22:15-21.
Dajani, E. Z., and N. M. Agrawal:Prevention of nonsteroidal anti-inflammatory druginduced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs. Digestive Diseases 1995; 13:48-61
Saegusa, Y, Takafumi I, Tomohisa I, Yukinobu G, Tomoaki I, Motoko N, et al.: Effects of acid antisecretory drugs on mucus barrier of the rat against 5fluorouracil-induced gastrointestinal mucositis. Scandinavia journal of gastroenterology 2008; 43:531-537.
Karnes JR, William E., and John H. Walsh: The Gastrin Hypothesis: Implication for Antisecretory Drug Selection. Journal of clinical gastroenterology 1990; 12:7-12.
Álvarez, Ángeles M, Sales Ibiza, Mario M. Andrade, García AB, Calatayud S: Gastric antisecretory drugs induce leukocyteendothelial cell interactions through gastrin release and activation of CCK-2 receptors. Journal of Pharmaceutical Experimental Therapeutics 2007; 1:406413.
Singh G, Triadafilopoulos G: Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAIDrelated gastrointestinal damage. International Journal of Clinical Practice 2005; 10:1210 – 1217 .
Mozdarani H: Radioprotective properties of histamine H2 receptor antagonists: present and future prospects. Journal of radiology research 2003; 2:145-149.
Sebastian SS, Kernan N, Qasim A, O'Morain CA, Buckley M: Appropriateness of gastric antisecretory therapy in hospital practice. Indian Journal of Medical Science 2004;3:115-117.
Maclaren R, ObritschMD, Sherman DS, Jung R, Fish DN: Assessing adherence to an intravenous pantoprazole guideline. Journal of Pharmacology & Technology 2006; 22:15-21.
Caro JJ, Salas M, Ward A: Healing and relapse rates in gastroeosophageal reflux disease treated with the newer protonpump inhibitors lansoprazole, rabeprazole and pantoprazole compared with omeprazole, ranitidine and placebo: clinical therapeutics 2001; 31(23):998-1017.
Baker DE: Intravenous proton pump inhibitors. Review in gastroentric disease 2006; 6(1):22.
Gawron AJ, Feinglass J, Pandolfino JE, Tan BK, Bove MJ, Shintani-Smith S. Brand Name and Generic Proton Pump Inhibitor Prescriptions in the United States: Insights from the National Ambulatory Medical Care Survey (2006 – 2010). Gastroenterology research and practice. 2015; Feb 5:2015.
Published
How to Cite
Issue
Section
Copyright (c) 2016 Laya Vahdati Rad, Divakar Goli, Binai K Sankar, Shiva Kumar

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at